Return to series page to register.

Join Dr. Amaal Starling to explore the impact of migraine, the current understanding of its pathophysiology, available treatment options, and the persistent knowledge gaps in addressing this disabling neurologic disease.

Migraine is a highly prevalent neurologic disease affecting approximately 12% of the global population, disproportionately affecting women. 1 in 5 women, 1 in 11 children, and 1 in 16 men have migraine. Migraine is a leading cause of disability worldwide. In fact, it is the #1 leading cause of years lived with disability for women in their most productive years. In the disease of migraine, people may experience severe, debilitating recurrent attacks of head pain accompanied by nausea, vomiting, sensitivity to light, sound, and movement. The pathophysiology of migraine involves complex interactions between genetic and environmental factors in the setting of abnormal neurologic function. In addition to lifestyle modifications and evidence based behavioral therapy, there are multiple medications for the acute and preventive treatment of migraine. Neuropeptides including calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating polypeptide play critical roles in migraine pathophysiology and have served as novel drug targets. Neuromodulation has also been another emerging treatment option. There continues to be persistent gaps in the diagnosis and treatment of migraine. Advocacy for people living with migraine focuses on increasing awareness, improving access to effective treatment options, and supporting research to better understand and manage this chronic neurologic disease.

Key Topics Include:

• Highlight the impact of migraine due to prevalence and disability


• Review the current understanding of migraine pathophysiology


• Explore the current treatment options for migraine


• Identify the persistent knowledge gaps in migraine